Publication | Open Access
Bisphosphonates target multiple sites in both <i>cis</i> - and <i>trans</i> -prenyltransferases
182
Citations
16
References
2007
Year
Drug TargetMolecular BiologyChemical BiologyFpps InhibitionMolecular PharmacologyMedicinal ChemistryInhibitory ActivityBiochemistryMechanism Of ActionBiochemical InteractionProtein PhosphorylationBinding SitesMolecular DockingSignal TransductionNatural SciencesMultiple SitesBisphosphonate DrugsCellular BiochemistryMedicineDrug Discovery
Bisphosphonate drugs (e.g., Fosamax and Zometa) are thought to act primarily by inhibiting farnesyl diphosphate synthase (FPPS), resulting in decreased prenylation of small GTPases. Here, we show that some bisphosphonates can also inhibit geranylgeranyl diphosphate synthase (GGPPS), as well as undecaprenyl diphosphate synthase (UPPS), a cis-prenyltransferase of interest as a target for antibacterial therapy. Our results on GGPPS (10 structures) show that there are three bisphosphonate-binding sites, consisting of FPP or isopentenyl diphosphate substrate-binding sites together with a GGPP product- or inhibitor-binding site. In UPPS, there are a total of four binding sites (in five structures). These results are of general interest because they provide the first structures of GGPPS- and UPPS-inhibitor complexes, potentially important drug targets, in addition to revealing a remarkably broad spectrum of binding modes not seen in FPPS inhibition.
| Year | Citations | |
|---|---|---|
Page 1
Page 1